This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Ixiaro
- Generic Name
- Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
- DrugBank Accession Number
- DB10769
- Background
Not Available
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Japanese encephalitis vaccine
- Japanese encephalitis vaccine IC51
- Japanese encephalitis virus (inactivated)
- Japanese encephalitis virus strain SA 14-14-2 antigen (formaldehyde inactivated)
- External IDs
- IC-51
- IC51
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Japanese encephalitis virus disease •••••••••••• ••••••••• Prevention of Japanese encephalitis virus disease •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ixiaro Injection, suspension 6 ug/0.5mL Intramuscular Vetter Pharma Fertigung GmbH & Co. KG 2009-03-30 Not applicable US 
Ixiaro Injection, suspension 6 AU Intramuscular Valneva Austria Gmb H 2020-12-23 Not applicable EU 
Ixiaro Injection, suspension 6 [arb'U]/0.5mL Intramuscular Valneva Scotland Ltd. 2009-03-30 Not applicable US Ixiaro Suspension 6 mcg / 0.5 mL Intramuscular Valneva Austria Gmbh 2009-12-29 Not applicable Canada 
Ixiaro Injection, suspension 6 AU Intramuscular Valneva Austria Gmb H 2020-12-23 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DZ854I04ZE
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Japanese Encephalitis / Vaccine Preventable Diseases / Vaccine Reaction 1 4 Completed Basic Science Japanese Encephalitis / Japanese Encephalitis Vaccine 1 4 Completed Prevention Encephalitis 1 4 Completed Prevention Japanese Encephalitis 1 4 Completed Prevention Japanese Encephalitis / Measles / Mumps / Rubella 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution 1 ml Injection, suspension Intramuscular 6 [arb'U]/0.5mL Injection, suspension Intramuscular 6 ug/0.5mL Injection, suspension Intramuscular 6 AU Injection, suspension Intramuscular; Subcutaneous 6 MCG Suspension Intramuscular 6 mcg / 0.5 mL Injection, suspension Intramuscular 6 mcg/0.5mL Injection Subcutaneous 1 ml Injection, powder, lyophilized, for solution 0.5 ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:04 / Updated at June 03, 2022 07:24